SSGCID
Seattle Structural Genomics Center for Infectious Disease

Cited Structures: list of articles citing SSGCID structures

We are actively tracking the number of publications by the scientific community which reference our structures, whether in the main text, figure captions or supplementary material. Selected articles are manually reviewed. Publications by SSGCID authors are excluded from the manually reviewed list. From our manual curation results, we estimate that the false positive rate might be as high as 50% for some structures.

This list was obtained from Google Scholar searches using an API provided by Christian Kreibich.

Cited structures

Manually reviewed citations

# PDB Additional SSGCID structures cited Link Title Year Citation Highlighted abstract
1 6x79 7jv2 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252571 Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors 2021 Baysal, N Abdul Ghafoor, RS Silme, AN Ignatov- PloS one, 2021 - journals.plos.org The 3' end of the genome encodes 4 major structural proteins, including the spike protein (S), the nucleocapsid protein structure of refusion SARS-CoV-2 S ectodomain trimer covalently stabilized in the closed conformation ( PDB : 6X79 ), and X-ray diffraction structure of SARS
2 6x79 - https://www.biorxiv.org/content/10.1101/2021.02.25.432861v3.abstract Antiviral Resistance against Viral Mutation: Praxis and Policy for SARS CoV-2 2021 RC Penner- BioRxiv, 2021 - biorxiv.org E of rotations of BHBs in HQ60; Table 1, Protein Data Bank structure files upon The methods of this paper are im- plented online from an uploaded PDB file at et al., Hydrogen bond rotations as a uniform structural tool for analyzing protein architecture , Nature Communications, 5
3 6x79 - https://pubs.acs.org/doi/abs/10.1021/acsomega.0c03512 Characterization of the SARS-CoV-2 S protein: biophysical, biochemical, structural, and antigenic analysis 2020 NG Herrera, NC Morano, A Celikgil, GI Georgiev- ACS, 2020 - ACS Publications need to produce large quantities of high-quality SARS-CoV-2 Spike (S) protein for use in both clinical and basic science settings. To address this need, we have evaluated the expression and purification of two previously reported S protein constructs in Expi293F and ExpiCHO-S cells... In nine structures that align well in this region (conformation 1: 6VXX, 6X29, 6X2C, 6X79, 6ZOX, 6ZOY, 6ZP0, 6ZP1, 6ZWV), the amino acid segment 621–640 was not modeled, presumably due to disorder
4 6wsa 3ppi, 3oxk, 3kcq, 4w5k, 3sgw, 4rgb, 4ghk https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257318 Principal component analysis of alpha-helix deformations in transmembrane proteins 2021 A Bevacqua, S Bakshi, Y Xia- PloS one, 2021 - journals.plos.org 6tt4, 6txw, 6tzj, 6uqw, 6v47, 6vbj, 6vie, 6vjd, 6vmz, 6vnw, 6w1w, 6w2x, 6wok, 6wsa , 6x1q, 6x2m and the contribution of each physical deformation to the overall flexibility of the secondary structure N -helices of a given length (L residues) were collected from PDB entries (See
5 6ws6 - https://www.sciencedirect.com/science/article/pii/S1931312820303620 Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 2020 JB Case, PW Rothlauf, RE Chen, Z Liu, H Zhao- Cell host &, 2020 - Elsevier Using an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput-imaging-based neutralization assay at biosafety level 2 ... VIR antibody set Pinto et al., 2020 S309 PDB: 6WS6
6 6ws6 - https://sciendo.com/pdf/10.2478/rrlm-2021-0022 Insights into Innate Immune Response Against SARS-CoV-2 Infection 2021 A Huanu, AM Georgescu, AV Andrejkovits- Revista Romn de, 2021 - sciendo.com The NET structure made by activated neutrophils and mediated by reactive oxygen species bacterial lipopolysaccharides (LPS), flagella, cilia, bacterial unmethylated DNA, or viral structures like dsARN or In addition, sev- eral structural and non- structural SARS-CoV-2 proteins
7 6ws6 - https://www.frontiersin.org/articles/10.3389/fimmu.2021.652223/full CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro 2021 MT Ma, S Badeti, CH Chen, J Kim- Frontiers in, 2021 - frontiersin.org Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is highly contagious and presents a significant public health issue. Current therapies used to treat coronavirus disease 2019 (COVID-19) include monoclonal antibody cocktail, convalescent plasma, antivirals ... Plasmid construct of S309-CAR. The SFG retroviral vector contains the S309 single chain antibody fragment (accession code 6WS6 on PDB)
8 6ws6 - https://www.science.org/doi/abs/10.1126/scitranslmed.abj7125 A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice 2021 DR Martinez, A Schfer, S Gobeil, D Li- Science translational, 2021 - science.org Binding and structural analysis showed high affinity binding of DH1047 to an epitope that is ACE2 (yellow surface representation, PDB 6VW1) binding to RBD is sterically hindered by
9 6wpt - https://hal.archives-ouvertes.fr/hal-03257466/document Hyaluronic Acid-2-Deoxy-D-Glucose Conjugate Act as a Promising Targeted Drug Delivery Option for the Treatment of COVID-19 2021 R Thirumalaisamy, V Aroulmoji- International, 2021 - hal.archives-ouvertes.fr of 2DG and HA-2DG was submitted to Online SMILES convertor and Structure file generator proteases Mpro (6LU7), papain like protease PLpro (6W9C), spike protein ( 6WPT ), RNA dependent RNA polymerase (6M71) was retrieved from RCSB PDB database (https
10 6wpt - https://www.nature.com/articles/s41467-020-18058-8 A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction 2020 M Ejemel, Q Li, S Hou, ZA Schiller, JA Tree- Nature, 2020 - nature.com COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. ... However, this predicted epitope of MAb362 is different from the other recently reported MAb complexes to the SARS-CoV-2-RBD (Fig. 3c and Supplementary Fig. 5), including: CR302217 (PDB: 6W41); S30916 (PDB: 6WPT); REGN10933 and REGN1098725;